Novogene and Pacific Biosciences to Jointly Develop and Co-Market Novel Applications Based on Sequel Platform
July 18 2017 - 8:00AM
Novogene, a leading global provider of genomic services and
solutions, and Pacific Biosciences of California, Inc.
(NASDAQ:PACB), the leader in long-read sequencing, have agreed to
jointly develop and promote novel applications based on the PacBio®
Sequel® System. New applications developed under this agreement are
expected to focus on basic and translational research in the field
of precision medicine, including methods for sample processing,
workflow automation, algorithm development, and database
construction.
Sequel Systems are based on Single Molecule, Real-Time (SMRT®)
technology, which has the advantage of uniform coverage across all
genome regions, including palindromes and low-diversity regions of
the genome. Genome sequencing with PacBio Systems helps
provide more complete and accurate views of all types of genomic
variation, revealing SNPs/SNVs, structural variants, mobile
elements, haplotypes, epigenetics, and variants in low-complexity
regions. Furthermore, the isoform sequencing (Iso-Seq®) method with
the Sequel System generates full-length cDNA sequences, which can
be used to profile the full complexity of the human
transcriptome and discover novel genes, isoforms, and gene
fusion events.
With the ability to run up to 10 PacBio Sequel Systems, Novogene
operates in a facility that has the largest capacity for SMRT
Sequencing in a single location. As a leading genomic service
provider with a comprehensive portfolio of service products,
Novogene has extensive expertise in developing and marketing
high-quality end-to-end service solutions, from sample preparation
to data analysis and interpretation, for a variety of applications
in diverse research and clinical fields.
About Novogene Corporation
Novogene is a leading provider of genomic services and solutions
with cutting edge NGS and bioinformatics expertise and one of the
largest sequencing capacities in the world. Novogene pursues
scientific excellence, strong commitment to customer service and
unsurpassed data quality to help our clients realize their research
goals in the rapidly developing world of genomics. With 1,800
employees, multiple locations around the world, 49 NGS related
patents, and over 250 publications in top tier journal such as
Nature and Science, Novogene has rapidly become a world-leader in
NGS services. For more information,
visit https://en.novogene.com/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de
novo genome assembly to finish genomes in order to more fully
identify, annotate and decipher genomic structures; full-length
transcript analysis to improve annotations in reference genomes,
characterize alternatively spliced isoforms in important gene
families, and find novel genes; targeted sequencing to more
comprehensively characterize genetic variations; and real-time
kinetic information for epigenome characterization. Pacific
Biosciences’ technology provides high accuracy, ultra-long reads,
uniform coverage, and the ability to simultaneously detect
epigenetic changes. PacBio® sequencing systems, including
consumables and software, provide a simple, fast, end-to-end
workflow for SMRT Sequencing. More information is available
at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to future uses, quality, performance or
advantages of, or benefits of using, products or technologies,
future development or promotional efforts, the expected benefits of
the company’s collaboration with Novogene, the suitability of the
company’s products for particular markets or applications and other
future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences’ control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences’ most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts:
For Novogene:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com
For PacBio:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024